The controversial interim final rule published by the Centers for Medicare & Medicaid Services (CMS) sets up a mandatory payment model surrounding the prices for 50 drugs administered under Medicare Part B, which reimburses providers for drugs administered in a clinic or hospital such as chemotherapy or vaccines. The drug prices are based upon the costs paid by foreign countries. The administration is pushing the rule to lower Medicare drug spending.
“This difference could become greater as the program moves forward. Normally, a drug price doesn’t change too much from quarter to quarter,” said Deepak A. Kapoor, MD. “The quarter-to-quarter variation is going to make it impossible for anyone to … significantly stock this type of drug, which results in a lot of inconveniences to patients because it makes it hard to time their visit,” Kapoor continued. “100% of the burden on this rule is on the providers, which makes colossally no sense.”
Learn more about this controversial interim final rule, by clicking here.